Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54 Week, Extension to the Double-blind, Multicenter, Multifactorial, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients

NCT00170976 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00170976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00170976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54 Week, Extension to the Double-blind, Multicenter, Multifactorial, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
June 30, 2005
Enrollment
403 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension